← Leaderboards
Powel H Brown
Baylor College Of Medicine
$10,794,797
Attributed
$13,542,521
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$16,844,045 · 9
By mechanism
R01$6,904,324 · 3
UG1$5,495,449 · 1
U19$3,301,524 · 1
P50$1,003,789 · 1
P30$98,959 · 1
R13$40,000 · 2
Top collaborators
- Eduardo Vilar Sanchez4 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Adrian Vincent Lee$9,294,282
- Meghana V Trivedi$280,151
- Powell H Brown$193,348
- Michael A Mancini$10,211,602
- Steffi Oesterreich$10,632,097
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventChemopreventionPharmaceutical PreparationsPreventionFutureCancer PreventionMolecularPathway InteractionsMalignant NeoplasmsIncidenceWomanBreastCellsBiological MarkersInhibitor/AntagonistTumorCancer Prevention TrialPrevention Clinical TrialOncogenicBaseMammary GlandCollaborationsBreast Cancer PreventionFoundations
Grant awards (42)
28 Cancer Prevention$18,707
P30 · FY2023 · CA · contact PI
iCAN-PREVENT: MD Anderson International Cancer Prevention Clinical Trial Consortium$911,328
UG1 · FY2022 · CA · contact PI
28 Cancer Prevention$18,707
P30 · FY2022 · CA · contact PI
iCAN-PREVENT: MD Anderson International Cancer Prevention Clinical Trial Consortium$1,822,363
UG1 · FY2021 · CA · contact PI
28 Cancer Prevention$18,707
P30 · FY2021 · CA · contact PI
iCAN-PREVENT: MD Anderson International Cancer Prevention Clinical Trial Consortium$1,814,563
UG1 · FY2020 · CA · contact PI
28 Cancer Prevention$18,676
P30 · FY2020 · CA · contact PI
iCAN-PREVENT: MD Anderson International Cancer Prevention Clinical Trial Consortium$947,195
UG1 · FY2019 · CA · contact PI
International Conference on Novel Strategies to Prevent Cancer by Targeting Infection, Inflammation, and the Immune System$20,000
R13 · FY2019 · CA · contact PI
28 Cancer Prevention$18,707
P30 · FY2019 · CA · contact PI
28 Cancer Prevention$5,455
P30 · FY2019 · CA · contact PI
10th International ICAPS Conference 2016 on Lung Cancer Prevention with a Consensus Conference on Early Detection and Prevention of Lung Cancer$20,000
R13 · FY2016 · CA · contact PI
Combination Chemoprevention: Prevention of Both ER-Positive & ER-Negative BC$224,390
P50 · FY2012 · CA · contact PI
Targeting AP-1 / ER Crosstalk for the Prevention and Treatment of Breast Cancer$291,194
R01 · FY2011 · CA · contact PI
Combination Chemoprevention: Prevention of Both ER-Positive & ER-Negative BC$227,821
P50 · FY2011 · CA · contact PI
Targeting AP-1 / ER Crosstalk for the Prevention and Treatment of Breast Cancer$300,200
R01 · FY2010 · CA · contact PI
Combination Chemoprevention: Prevention of Both ER-Positive & ER-Negative BC$239,733
P50 · FY2010 · CA · contact PI
Targeting AP-1 / ER Crosstalk for the Prevention and Treatment of Breast Cancer$285,000
R01 · FY2009 · CA · contact PI
Combination Chemoprevention: Prevention of Both ER-Positive & ER-Negative BC$156,407
P50 · FY2009 · CA · contact PI
Targeting AP-1 / ER Crosstalk for the Prevention and Treatment of Breast Cancer$285,000
R01 · FY2008 · CA · contact PI
Molecular Mechanisms by which Rexinoids Prevent Breast Cancer$205,205
R01 · FY2008 · CA · contact PI
Combination Chemoprevention: Prevention of Both ER-Positive & ER-Negative BC$155,438
P50 · FY2008 · CA · contact PI
Molecular Mechanisms by which Rexinoids Prevent Breast Cancer$135,880
R01 · FY2008 · CA · contact PI
Prevention of Estrogen Receptor-negative Breast Cancer$475,923
R01 · FY2007 · CA · contact PI
Molecular Mechanisms by which Rexinoids Prevent Breast Cancer$337,707
R01 · FY2007 · CA · contact PI
Targeting AP-1 / ER Crosstalk for the Prevention and Treatment of Breast Cancer$285,000
R01 · FY2007 · CA · contact PI
Prevention of ER-negative Breast Cancer: Identification*$477,939
R01 · FY2006 · CA · contact PI
Molecular Mechanisms by which Rexinoids Prevent BRCA$337,663
R01 · FY2006 · CA · contact PI
Prevention of ER-negative Breast Cancer: Identification*$487,994
R01 · FY2005 · CA
Molecular Mechanisms by which Rexinoids Prevent BRCA$342,308
R01 · FY2005 · CA
CHEMOPREVENTION OF BREAST AND OVARIAN CANCER$736,356
U19 · FY2004 · CA
Prevention of ER-negative Breast Cancer: Identification*$465,456
R01 · FY2004 · CA
Molecular Mechanisms by which Rexinoids Prevent BRCA$342,682
R01 · FY2004 · CA
Prevention of ER-negative Breast Cancer$464,524
R01 · FY2003 · CA
PREVENTION OF BREAST CANCER USING SELECTIVE RETINOIDS$359,698
R01 · FY2003 · CA
CHEMOPREVENTION OF BREAST AND OVARIAN CANCER$334,815
U19 · FY2003 · CA
CHEMOPREVENTION OF BREAST AND OVARIAN CANCER$1,011,836
U19 · FY2002 · CA
PREVENTION OF BREAST CANCER USING SELECTIVE RETINOIDS$352,756
R01 · FY2002 · CA
PREVENTION OF BREAST CANCER USING SELECTIVE RETINOIDS$351,034
R01 · FY2001 · CA
CHEMOPREVENTION OF BREAST AND OVARIAN CANCER$252,539
U19 · FY2001 · CA
CHEMOPREVENTION OF BREAST AND OVARIAN CANCER$965,978
U19 · FY2000 · CA
PREVENTION OF BREAST CANCER USING SELECTIVE RETINOIDS$321,161
R01 · FY2000 · CA